Columbia research finds that people with schizophrenia who have difficulty hearing subtle changes in pitch may be helped with auditory training and a drug targeting NMDA receptors.
A mood-stabilizing drug prescribed to many patients with schizophrenia or bipolar disorder may decrease negative symptoms for people with a certain variant of the COMT gene.
The biomarker is an important step toward understanding and treating one of the most devastating symptoms of schizophrenia.
Researchers have found that treatment with very low doses of a dopamine-1 receptor (D1R) agonist was not effective in reducing the cognitive and negative symptoms of schizophrenia.
In studies in mice, Zuckerman Institute researchers have discovered a way to restore memory deficits found in schizophrenia by regrowing lost neuronal connections.